ERX1589911 E-MTAB-4851:CR1_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237150 SAMEA4066040 CR1_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: resistant drug response ERX1589912 E-MTAB-4851:CR2_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237151 SAMEA4066041 CR2_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: resistant drug response ERX1589913 E-MTAB-4851:CR4_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237152 SAMEA4066042 CR4_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: resistant drug response ERX1589914 E-MTAB-4851:CR5_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237153 SAMEA4066043 CR5_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: resistant drug response ERX1589915 E-MTAB-4851:CR6_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237154 SAMEA4066044 CR6_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: resistant drug response ERX1589916 E-MTAB-4851:CR7_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237155 SAMEA4066045 CR7_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: resistant drug response ERX1589917 E-MTAB-4851:CS_p ERP016370 Emergence of resistance to tyrosine kinase inhibitors in non-small cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib ERS1237156 SAMEA4066046 CS_p WXS GENOMIC cDNA The crizotinib-resistant H2228 cell lines (H2228-CR) were generated in house and derived from EML4-ALK H2228 xenograft tumours, which acquired resistance to crizotinib in vivo after continuous crizotinib monotherapy. DNA isolation performed by GATC Biotech Exome enrichment performed using Agilent SureSelect Human All Exon v5 202 0 F Application Read Forward 1 1 R Application Read Reverse 102 Illumina HiSeq 2500 Experimental Factor: sensitive drug response